Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,417.53 -0.15 -0.00%
TOPIX 1,166.59 0.04 0.00%
HANG SENG 22,760.24 64.23 0.28%

Halozyme Therapeutics And Pfizer Enter Into A Collaboration To Develop And Commercialize Subcutaneous Biologics Using



  Halozyme Therapeutics And Pfizer Enter Into A Collaboration To Develop And
  Commercialize Subcutaneous Biologics Using Recombinant Human Hyaluronidase

PR Newswire

SAN DIEGO, Dec. 21, 2012

SAN DIEGO, Dec. 21, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:
HALO) announced today that it has entered into a worldwide Collaboration and
License Agreement with Pfizer Inc. (NYSE: PFE) for the purpose of developing
and commercializing products combining proprietary Pfizer biologics with
Halozyme's Enhanze™ technology. Enhanze is Halozyme's proprietary drug
delivery platform and is based on the Company's patented recombinant human
hyaluronidase enzyme (rHuPH20).

(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

Under the terms of the agreement, Halozyme has granted to Pfizer a worldwide
license to develop and commercialize products combining rHuPH20 with Pfizer
proprietary biologics directed to up to six targets. Targets may be selected
on an exclusive or non-exclusive basis.  Halozyme will receive an initial
payment of $8 million, which includes the upfront fee for exclusive licenses
to two specified therapeutic targets in primary care and specialty care
indications and the right for Pfizer to elect up to four additional targets
upon payment of additional fees.

"I am delighted about this opportunity as it has the potential to enhance
Pfizer's ability to optimize treatments for patients," said Jose Carlos
Gutierrez-Ramos, Senior Vice President, Pfizer BioTherapeutics R&D.

Halozyme is eligible to receive additional payments upon Pfizer's achievement
of specified development, regulatory and sales-based milestones, totaling up
to $507 million. Halozyme is also entitled to royalty payments based on net
sales of any licensed products.

"We look forward to working with Pfizer to apply Enhanze to these exciting
targets," said Gregory I. Frost, Ph.D., President and Chief Executive Officer,
Halozyme. "Enhanze enables biologics to be delivered as a simple subcutaneous
injection."

About ENHANZE™
Enhanze is Halozyme's proprietary drug delivery platform based on the
Company's patented recombinant human hyaluronidase enzyme (rHuPH20). rHuPH20
acts by removing traditional limitations on the volume of biologics that can
be delivered subcutaneously (just under the skin). By using Enhanze, some
biologics that are administered intravenously may instead be delivered
subcutaneously. Enhanze may also benefit subcutaneous biologics by reducing
the need for multiple injections. This delivery may improve patient
convenience and reduce overall costs to the healthcare system.

About Halozyme
Halozyme Therapeutics is a biopharmaceutical company dedicated to developing
and commercializing innovative products that advance patient care. With a
diversified portfolio of enzymes that target the extracellular matrix, the
Company's research focuses primarily on a family of human enzymes, known as
hyaluronidases, that increase the absorption and dispersion of biologics.
Halozyme's pipeline addresses therapeutic areas, such as diabetes, oncology
and dermatology that have significant unmet medical need. The Company markets
HYLENEX^® recombinant (hyaluronidase human injection) and has partnerships
with Roche, Baxter, ViroPharma and Intrexon. Halozyme is headquartered in San
Diego, CA. For more information on how we are innovating, please visit our
corporate website at www.halozyme.com.

Safe Harbor Statement
In addition to historical information, the statements set forth above include
forward-looking statements (including, without limitation, statements
concerning the development and commercialization of products, the potential
benefits and attributes of such products, the possible receipt by Halozyme of
future payments including milestone and royalties) that involve risk and
uncertainties that could cause actual results to differ materially from those
in the forward-looking statements. The forward-looking statements are also
identified through use of the words "believe," "enable," "may," "will,"
"could," "intends," "estimate," "anticipate," "plan," "predict," "probable,"
"potential," "possible," "should," "continue," and other words of similar
meaning. Actual results could differ materially from the expectations
contained in forward-looking statements as a result of several factors,
including unexpected results or delays in development and regulatory review,
regulatory approval requirements, unexpected adverse event and competitive
conditions. These and other factors that may result in differences are
discussed in greater detail in the Company's reports on Forms 10-K, 10-Q, and
other filings with the Securities and Exchange Commission.

Investor Contact:
Kurt Gustafson
Halozyme Therapeutics
858-704-8272
kgustafson@halozyme.com

Media Contact:
Nurha Hindi
Hill + Knowlton Strategies
818-522-8411
Nurha.Hindi@hkstrategies.com

SOURCE Halozyme Therapeutics, Inc.

Website: http://www.halozyme.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement